ORIC Pharma, Cancer Research UK to Advance CIP2A Therapy

ORIC Pharmaceuticals announced an agreement with Cancer Research UK to advance its potential first-in-class CIP2A-targeted therapy, ORIC-259, into clinical development. Cancer Research UK will fund, sponsor, design, and execute studies and Phase 1/2 clinical development, while ORIC retains an option to reacquire rights.